Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Real-world data support adjuvant immunotherapy for stage III melanoma

Key clinical point: Immunotherapy after resection of the primary tumor improved survival among patients with stage III melanoma, particularly those with stage IIIC disease.

Major finding: In the stage IIIC group, the 2-year survival rate was 70% in patients who received immunotherapy and 59% in those who did not (P < .01).

Study details: Review of data from 8,160 patients with stage III melanoma, 4,094 of whom were included in the survival analysis.

Disclosures: There was no external funding. The presenter disclosed travel compensation from Astellas Pharmaceuticals in 2018.

Citation:

Moyers J et al. AACR 2020, Abstract 4338.